Final analysis of the POEMS (Prevention of Early Menopause) study finds that breast cancer (BC) patients treated with the gonadotrophin-releasing hormone agonist (GnRHa) goserelin, in addition to chemotherapy, are more likely to avoid premature menopause and to become pregnant without negatively impacting disease-related outcomes.
The combination of androgen deprivation therapy (ADT) with abiraterone acetate and prednisolone (AAP) treatment is effective against metastatic hormone-naïve prostate cancer (mHNPC) regardless of risk stratification, a recent study has shown.
The widely adopted practice of secondary surgical cytoreduction in women with platinum-sensitive recurrent ovarian cancer is being called into question as a phase III trial shows no improvement in overall survival (OS) with this approach.
In cancer patients with rheumatoid arthritis (RA) treated with immune checkpoint inhibitors (ICIs), rates of immune-related adverse events (irAEs) are similar to those reported in patients without autoimmune diseases, with most symptoms being manageable.
Treatment with cabazitaxel in patients with metastatic castration-resistant prostate cancer (mCRPC) results in a slightly lower median overall survival (OS) at 18 months as compared with that in the pivotal clinical trial, owing to the presence of features of poor prognosis at baseline and use of cabazitaxel in third line or beyond in 82 percent of patients, according to the FUJI study.
The incidence of both hypercalcaemia and hypocalcaemia in cancer patients with bone metastasis appears to be higher with denosumab as compared to zoledronic acid, a recent study has shown. Moreover, adequate supplementation with calcium helps lower the risk of hypocalcaemia.
Lenvatinib, a vascular endothelial growth factor receptor (VEGFR) tyrosine kinase inhibitor for thyroid and renal malignancies, seems to play a role in wound healing complications based on temporality and biologic plausibility, suggests evidence from the US Food and Drug Administration (FDA) Adverse Event Reporting System (FAERS).
The triplet regimen of encorafenib, binimetinib and cetuximab provides significant and clinically relevant benefits in overall survival (OS) and objective response rate (ORR) in patients with BRAFV600E-mutated metastatic colorectal cancer (mCRC) who experience disease progression after one or two previous regimens, according to results of an interim analysis of the BEACON CRC trial.
New drug applications approved by US FDA as of 01 - 15 November 2019 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.